As a representative example, EVs engineered to encapsulate adeno-associated virus (AAV) vectors expressing tumor-associated antigens (e.g., ovalbumin [OVA], tyrosinase-related protein 1 [TRP-1]) demonstrated superior antigen-specific CD8+ T-cell priming efficacy compared to conventional AAV delivery platforms. Here, CD8A is linked to neoplasm.